Precigen (NASDAQ:PGEN) Stock Price Down 7.5% – Should You Sell?

Precigen, Inc. (NASDAQ:PGEN) fell 7.5% during trading on Monday . The company traded as low as $4.23 and last traded at $4.2450. 1,422,310 shares changed hands during trading, a decline of 58% from the average session volume of 3,377,105 shares. The stock had previously closed at $4.59.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on PGEN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of Precigen from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Finally, HC Wainwright upped their price target on shares of Precigen from $8.50 to $9.00 and gave the company a “buy” rating in a research report on Friday, November 14th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $8.50.

Precigen Price Performance

The stock has a market cap of $1.46 billion, a PE ratio of -2.98 and a beta of 1.10. The business has a fifty day simple moving average of $4.05 and a two-hundred day simple moving average of $3.37. The company has a current ratio of 4.04, a quick ratio of 3.95 and a debt-to-equity ratio of 2.22.

Precigen (NASDAQ:PGEN) last released its earnings results on Thursday, November 13th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). The business had revenue of $2.92 million during the quarter, compared to analysts’ expectations of $0.67 million. Precigen had a positive return on equity of 1,066.10% and a negative net margin of 3,912.92%. Research analysts forecast that Precigen, Inc. will post -0.32 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Randal J. Kirk sold 1,900,036 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $4.18, for a total transaction of $7,942,150.48. Following the sale, the director directly owned 341,189 shares of the company’s stock, valued at $1,426,170.02. This trade represents a 84.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last quarter, insiders sold 4,866,329 shares of company stock worth $20,233,899. Company insiders own 47.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Inspire Investing LLC bought a new stake in Precigen during the 1st quarter worth approximately $350,000. Diametric Capital LP purchased a new stake in shares of Precigen in the second quarter worth about $476,000. Voya Investment Management LLC boosted its position in shares of Precigen by 142.9% during the 1st quarter. Voya Investment Management LLC now owns 36,771 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 21,633 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Precigen in the third quarter valued at $41,000. Finally, Barclays PLC increased its position in Precigen by 81.4% in the third quarter. Barclays PLC now owns 555,856 shares of the biotechnology company’s stock worth $1,829,000 after purchasing an additional 249,438 shares during the last quarter. Institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.